Dr. Deepa Jeyakumar, MD

Dr. Jeyakumar practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Jeyakumar's NPI, 1356541502, was assigned on July 24, 2007. Dr. Jeyakumar graduated from Lewis Katz School of Medicine in 2005. Dr. Jeyakumar's California license number on file is A121651.

Dr. Jeyakumar's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Jeyakumar's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jeyakumar practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Jeyakumar's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Jeyakumar is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Jeyakumar's licenses on file in 3 states: California, Massachusetts and Illinois.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, deep vein thrombosis (DVT), fluid and electrolyte imbalances, lung cancer and lymphoma among the conditions Dr. Jeyakumar treats.

CMS data shows 546 Medicare services from Dr. Jeyakumar across 5 procedure codes in 2024, for 111 Medicare patients. Medicare paid $59,582 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 111 Medicare patients who saw Dr. Jeyakumar in 2024. The largest group is 75 to 84, with 51 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 42% are also on Medicaid. Their average risk score is 3.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jeyakumar's median patient age at 66, with 48% women.

In 2024, Dr. Jeyakumar wrote 878 Medicare Part D claims for 70 patients. 72% of them were for generic drugs. CMS names the drug for 554 of them, across 19 drugs with 11 or more claims each, at $1,573,263 in total drug cost. In 2023, CMS named 484 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Jeyakumar for performance year 2024, reported through an alternative payment model (APM). Dr. Jeyakumar accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Jeyakumar as offering telehealth.

Dmand AI links 25 papers to Dr. Jeyakumar, published from 2005 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents and DNA, Viral. Dr. Jeyakumar has published most often in Am J Hematol. Dr. Jeyakumar's most frequent co-authors are Stefan Octavian Ciurea, MD, Piyanuch Kongtim, MD, PhD and Emily Blodget, BAO, BCH, MB, MD.

Dmand AI links Dr. Jeyakumar to 8 clinical trials, 3 of them phase 3 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Burkitt Lymphoma. National Cancer Institute (NCI) sponsors the most, 4.

CMS Open Payments shows 55 general payments to Dr. Jeyakumar from 12 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 69% of the total. Celgene Corporation paid the most, $34,030. It also lists 2 research payments totaling $3,269 in 2023.

Dr. Jeyakumar graduated from Lewis Katz School of Medicine in 2005. Dr. Jeyakumar is a member of ASH.

Dr. Jeyakumar is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.